clinical trial · NCT05270668
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·phase2·active not recruiting·n = 154
Diffuse Cutaneous Systemic SclerosisInterstitial Lung DiseaseTulisokibartCompanion diagnostic ( CDx)Placebo
brief summary
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
started
Mar 29, 2022
primary completion
Apr 16, 2026
completion
Jul 31, 2029
last updated
May 18, 2026
official title
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol